Amgen's MariTide phase 2 study shows 'meaningful' reduction in blood sugar, weight
I'm PortAI, I can summarize articles.
Jan 12 (Reuters) - Amgensaid on Monday a 24-week study of monthly doses of its experimental obesity drug MariTide in people with type 2 diabetes showed “robust and clinically meaningful” reduction in both blood sugar and weight.In a 52-week extension study, a large majority of participants who received a lower monthly dose or a quarterly dose maintained the weight loss achieved during the initial phase 2 trial, the company said.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments